Event Recap | Key Insights from the 2025 J.P. Morgan Healthcare Conference (With Report Materials)

Recently, the 43rd J.P. Morgan Healthcare Conference (JPM Conference) has slowly come to an end in San Francisco, USA.Including AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche, GSK and many other well-known pharmaceutical companies attended as scheduled, showcasing their company developments and latest strategies.

GBB team attended this grand event and listened to the on-site report.Known as the industry barometer of global pharmaceutical investment, what industry signals did this year's JPM Conference reveal? (Get materials at the end of the article)

During the conference, Roche revealed that in the ADC and innovative target fields, AI might be utilized to enhance pharmaceutical productivity, reduce costs, and support the development of next-generation drugs. Similarly, a Bain report also pointed out that the application of AI in the biopharmaceutical field has rapidly expanded from initial auxiliary diagnosis and image analysis to core areas such as early drug discovery, clinical trial design, patient stratification, and precision medicine.

During this conference, bispecific and multispecific antibodies were highly sought after. Merus NV and Biohaven jointly announced a collaboration to develop three novel bispecific antibody-drug conjugates. Additionally, AbbVie announced a licensing option agreement with Simcere Zaiming for the GPRC5D-BCMA-CD3 trispecific antibody SIM0500, with upfront and milestone payments totaling up to $1.055 billion.

Chinese pharmaceutical companies are appearing more frequently, with nearly 30 companies participating. Innovative drugs produced in China are showing a reversal from "import" to "export." The organizers carefully arranged for three highly influential elite figures in their respective fields, who all coincidentally mentioned the rise of China's pharmaceutical industry in their speeches, expressing varying degrees of complex emotions.

GBB leverages cutting-edge technologies such as artificial intelligence, big data mining, and automation to drive drug development, demonstrating significant advantages in accelerating clients' rapid market entry and supporting the overseas expansion of their products, especially bispecific antibody products.GBB's multiple intelligent drug discovery and CMC development platforms have helped clients obtain the approval of China's National Medical Products Administration (NMPA) and the Investigational New Drug (IND) tacit approval from the U.S. Food and Drug Administration (FDA). In the process of internationalization, GBB has established partnerships with several multinational giants in the fields of life sciences, specialty chemicals, and pharmaceutical CDMOs.

Forward this tweet to your WeChat Moments, scan the QR code below to contact our customer service and send a screenshot to receive first-hand reports from major pharmaceutical companies such as AstraZeneca, Eli Lilly, Novartis, Pfizer, Roche, and GSK at the JPM Conference.